The utility of non-HDL in managing dyslipidemia of Stage 5 chronic kidney disease

Clinical Nephrology

Volumn 66, Issue 5, 2006, Pages 336-347

  Pennell, P ^a   Leclercq, B ^a   Delahunty, M J ^b   Walters, B A J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Gambro AB   (Sweden)

Author keywords

Chronic kidney disease; Dyslipidemia; Non HDL cholesterol; Treatment guidelines; VLDL

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 33750868782     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66336     Document Type: Article

References (34)

1. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993; 104: 159-171.
2. Assmann G, Schulte H, Funke H, Von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998; 19 (Suppl M): M8-M14.
3. Attman P, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21. 573-592.
4. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998; 81: 7B-12B.
5. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis. 1992; 20: 324-335.
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.
7. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langengerg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001; 161: 1413-1419.
8. Desmeules S, Arcand-Boose J, Bergeron J, Douville P, Agharazii M. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis. 2005; 45: 1067-1072.
9. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
10. Grundy SM, Vega GL. Hypertriglyceridemia: Causes and relation to coronary heart disease. Semin Thromb Hemostas. 1998; 14: 149-164.
11. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Int Med. 1992; 152: 28-34.
12. Grundy SM, Cleeman JI, Merz CNB, Brewer B, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
13. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997; 95: 2022-2026.
14. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997; 12: 2597-2602.
15. Kasiske B. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998; 32 (Suppl 3). S142-S156.
16. Koba S, Hirano T, Sakaue T, Takeuchi H, Adachi M, Katagiri T. An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men independently of intermediate-density lipoprotein or low-density lipoprotein. Coron Artery Dis. 2002; 13: 255-262.
17. Lee DM, Knight-Gibson C, Samuelsson O, Attman P, Wang C, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int. 2002; 61: 209-218.
18. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PWF, Wright JT. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998; 32: 853-906.
19. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ. Association between cholesterol level and mortality in dialysis patients. JAMA. 2004; 291: 451-459.
20. McCosh EJ, Solangi K, Rivers JM, Goodman A. Hypertriglyceridemia in patients with chronic renal insufficiency. Am J Clin Nutr. 1975; 28: 1036-1043.
21. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on Cardiovascular Disease. J Am Soc Nephrol. 1998; 9 (Suppl 12): S31-S42.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003; 41 (Suppl 3): S1-S91.
23. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int. 2003; 63 (Suppl 84): S117-S120.
24. Quaschning T, Krane V, Metsger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis. 2001; 38 (Suppl 1): S14-S19.
25. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154-2169.
26. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61: 297-304.
27. Shoji T, Nishizawa Y, Kawagishi T, Tanaka T, Kawasaki K, Tabata T, Inoue T, Morii H. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis. 1997; 131: 229-236.
28. Shoji T, Nishizawa Y, Kawagishi T, Kaasaki K, Taniwaki H, Tabata T, Inoue T, Morii H. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol. 1998; 9: 1277-1284.
29. Shoji T, Ishimura E, Masaaki I, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis. 2001; 38 (Suppl 1): S30-S33.
30. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996; 276: 882-888.
31. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, Miyauchi K. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995; 41: 717-723.
32. Tanaka A, Ali M, Kobayashi Y, Tamura M, Shimokado K, Numano F. Metabolism of triglyceride-rich lipoproteins and their role in atherosclerosis. Ann N Y Acad Sci. 2001; 947: 207-212.
33. Topol EJ. Intensive statin therapy? A sea change in cardiovascular prevention. N Engl J Med. 2004; 350: 1562-1564.
34. United States Renal Data System USRDS. 2002 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003; 41 (Suppl 2): S1-S256.